Sponsored

Prescient (ASX: PTX) shares jump 6% on new US patent

July 05, 2022 06:29 AM CEST | By Aditi Sarkar

Highlights

  • Prescient Therapeutics (ASX:PTX) bags a US patent (providing protection until at least 2039) for its OmniCAR portfolio "SpyCatcher and SpyTag: Universal Immune Receptor For T Cells"
  • OmniCAR is a universal immune receptor platform creating controllable, adaptable, and flexible next generation of modular cell therapies
  • Securing a US patent helps PTX to safeguard the OmniCAR platform in the world's biggest healthcare market.

In an exciting update, Prescient Therapeutics (ASX:PTX) has announced that it has been granted a key US Patent for its OmniCAR portfolio "SpyCatcher and SpyTag: Universal Immune Receptor For T Cells". This patent will provide protection in the world’s largest healthcare market, the US.  

Following this news, shares of the company zoomed up 6% to AU$0.175 (05JULY2022, 10:54 AM AEST).

Prescient is a clinical-stage oncology company having a pipeline of universal Chimeric Antigen Receptor (CAR)-T and targeted therapies against cancer.

Image source: © 2022 Kalkine Media®

OmniCAR

OmniCAR is a universal immune receptor (UIR) platform creating controllable, adaptable, and flexible next generation of modular cell therapies. The major component of the OmniCAR platform is a two-part covalent binding system – called SpyTag and SpyCatcher – which enables modularity. It was developed and licensed by Oxford University.

The University of Pennsylvania applied the novel binding system to cell therapy, described in the patent, which has been exclusively licensed to Prescient. The patent safeguards the molecules currently being developed by Prescient for use in the OmniCAR platform until at least 2039.

According to Prescient, OmniCAR is the only UIR system currently known to use covalent binding, a highly powerful chemical bond. As compared to alternative strategies that rely on weaker, transient binding, OmniCAR's covalent binding of UIRs gives several significant advantages, including higher efficacy, control, and the capacity to pre-arm T cells.

To know more about Prescient Therapeutics Limited, click here. Also, to stay updated with PTX company activities and announcements, please update your details on their investor centre.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Recent Articles